Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome.
Antonella TramutolaChiara LanzillottaEugenio BaroneAndrea ArenaIlaria ZulianiLuciana MoscaCarla BlarzinoD Allan ButterfieldMarzia PerluigiFabio Di DomenicoPublished in: Translational neurodegeneration (2018)
These findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis, thus ultimately resulting in improved cognition. Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals.
Keyphrases
- cognitive decline
- mild cognitive impairment
- mouse model
- cerebral ischemia
- preterm infants
- cancer therapy
- white matter
- protein protein
- gestational age
- amino acid
- human health
- small molecule
- multiple sclerosis
- cognitive impairment
- risk assessment
- brain injury
- blood brain barrier
- subarachnoid hemorrhage
- climate change
- drug induced
- prefrontal cortex